2023-04-26 16:48:46 ET
- Nevro press release ( NYSE: NVRO ): Q1 GAAP EPS of -$0.98 beats by $0.06 .
- Revenue of $96.3M (+9.6% Y/Y) beats by $0.95M .
- First Quarter 2023 Non-GAAP Adjusted EBITDA Loss of $17.1M.
- Guidance: Provides Second Quarter 2023 Revenue Guidance of $110 Million to $112 Million vs. consensus of $111.17M; Reiterates Full-Year 2023 Revenue Guidance of $445 Million to $455 Million, or 10% to 12% Constant Currency Growth Over 2022 vs. consensus of $449.09M; Full-Year Guidance Includes PDN Indication Sales of Approximately $75 Million to $85 Million, or 56% to 77% Growth Over 2022
- Provides Second Quarter of 2023 Non-GAAP Adjusted EBITDA Guidance of Negative $4 Million to Negative $5 Million; Reiterates Full-Year 2023 Non-GAAP Adjusted EBITDA Guidance of Negative $5 Million to Negative $10 Million.
For further details see:
Nevro beats Q1 top and bottom line estimates; initiates Q2 and reaffirms FY23 outlook